{"filings":[{"id":582800,"accession_number":"0001437749-26-018106","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2026-05-21T20:30:35+00:00","items":["5.07"],"status":"ready","headline":"DiaMedica shareholders re-elect all seven directors, approve auditor, exec compensation, and share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven incumbent directors re-elected; Daniel O'Connor received 5,130,879 votes withheld vs. ~200,000 for others.","Baker Tilly US, LLP ratified as auditor for FY 2026 with 20,950,404 votes for and 578,926 against.","Advisory vote on executive compensation approved: 9,928,381 for, 271,093 against, 149,163 abstain.","Amendment to 2019 Omnibus Incentive Plan to increase shares by 3.5M approved: 9,693,413 for, 510,487 against.","All proposals passed with broker non-votes of 11,180,693 on director election and other non-routine items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92635,"accession_number":"0001437749-26-015218","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DiaMedica Q1 net loss $10M; cash $51.3M; ReMEDy2 >70% enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.0M in Q1 2026 vs $7.7M in Q1 2025; R&D expenses up to $8.0M from $5.7M.","Cash $51.3M as of March 31, 2026, down from $59.9M; company expects runway through 2027.","ReMEDy2 Phase 2/3 acute ischemic stroke trial surpassed 70% of required enrollment; interim analysis planned Q4 2026.","Preeclampsia Phase 2 IST expansion cohort enrolling; updated dataset expected in Q2 2026.","Rabbit study showed antibody response to DM199, preventing fetal development study; awaiting FDA response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103604,"accession_number":"0001437749-26-010409","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DiaMedica reports FY2025 cash $59.9M; ReMEDy2 trial nearing 70% interim enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $59.9M at Dec 31, 2025, up from $44.1M; runway through 2H 2027.","ReMEDy2 Phase 2/3 AIS trial approaching 70% of required interim enrollment; analysis in 2H 2026.","R&D expenses $24.6M vs $19.1M YoY driven by ReMEDy2 expansion and PE program costs.","G&A expenses $9.8M vs $7.6M YoY; net cash used in ops $29.1M vs $22.1M.","PE Phase 2 IST Part 1a enrollment ongoing; DiaMedica-sponsored Phase 2 to start later 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103603,"accession_number":"0001437749-26-000175","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DiaMedica raises $12.2M via block sale of 1.5M shares at $8.10 under ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,501,000 common shares to a healthcare institution fund on Dec 19, 2025.","Gross proceeds of $12.2 million at $8.10 per share via an at-the-market offering.","Net proceeds after fees and expenses not disclosed in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119874,"accession_number":"0001437749-25-038211","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"DiaMedica provides DM199 preeclampsia update after FDA pre-IND meeting; additional rabbit study required","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA requested one non-clinical 10-day rabbit EFD/PPND study; results expected by Q2 2026.","Phase 2 investigator-sponsored trial in South Africa has dosed over 30 women with late-stage PE.","Interim data: statistically significant blood pressure reductions, uterine artery dilation, no placental transfer.","Regulatory clarity obtained for IND submission to study DM199 in early-onset preeclampsia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119873,"accession_number":"0001437749-25-034467","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DiaMedica Q3 net loss $8.6M; ReMEDy2 trial at 50% enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.6M in Q3 2025, up from $6.3M a year ago; R&D expense $6.4M, up from $5.0M.","Cash and short-term investments $55.3M as of Sept 30, 2025; funded into 2H 2027.","ReMEDy2 Phase 2/3 AIS trial enrollment nearing 50% of 200-patient interim target.","Preeclampsia IST Part 1a expansion cohort enrolling; Part 3 fetal growth restriction screening starting soon.","Pre-IND meeting with FDA on DM199 for preeclampsia held; update after minutes received."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136439,"accession_number":"0001437749-25-026286","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"DiaMedica enters $100M ATM equity distribution agreement with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $100M in common shares may be sold through TD Cowen as sales agent.","TD Cowen earns up to 3.0% commission on gross proceeds from ATM sales.","Sales cannot occur until the related Form S-3 shelf registration is declared effective.","Proceeds use not specified; agreement includes customary indemnification provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136438,"accession_number":"0001437749-25-026205","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DiaMedica Therapeutics Reports Q2 2025 Financial Results and Positive Phase 2 Interim Data for DM199 in Preeclampsia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 Part 1a interim data (n=28) showed statistically significant reductions in blood pressure and uterine artery pulsatility index with no placental transfer of DM199.","Raised $30.1 million in July 2025 private placement, extending proforma cash to ~$60M and funding operations into H2 2027.","ReMEDy2 Phase 2/3 trial for acute ischemic stroke enrollment progressing; interim analysis on first 200 patients expected Q2 2026.","Appointed Julie Krop, MD, as Chief Medical Officer in August 2025; added to Russell 2000 and 3000 Indexes in June 2025.","Net loss for Q2 2025 was $7.7 million, up from $5.1 million in Q2 2024; R&D expenses increased to $5.8 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136437,"accession_number":"0001437749-25-024956","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"DiaMedica CMO Lorianne Masuoka resigns; Julie Krop appointed as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lorianne Masuoka resigned as CMO effective Aug 4, 2025 for personal reasons; separation agreement provides health benefits through Oct 2026.","Julie Krop appointed as CMO effective Aug 11, 2025; Krop brings 20+ years experience, most recently CMO at PureTech Health.","Krop previously CMO at Freeline Therapeutics and AMAG Pharmaceuticals; involved in preeclampsia drug development at AMAG.","Krop will lead clinical development of DM199 for preeclampsia and acute ischemic stroke."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136436,"accession_number":"0001437749-25-023048","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"DiaMedica raises $30.1M via private placement of 8.6M shares at $3.50 to fund preeclampsia pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 8,606,426 common shares at $3.50 per share, raising $30.1M gross proceeds.","Closing expected July 23, 2025; no placement agent engaged.","Proceeds to support DM199 IND submission and Phase 2b study for preeclampsia and fetal growth restriction.","Registration rights agreement requires filing resale registration statement within 10 business days of closing.","Transaction involves non-management related parties; exempt from Canadian MI 61-101 valuation/minority approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136435,"accession_number":"0001437749-25-022877","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"DiaMedica reports positive Phase 2 preeclampsia data: BP reductions, no placental transfer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DM199 highest dose (Cohort 9, n=3): SBP -35 mmHg (p<0.05), DBP -15 mmHg (p<0.05) at 5 min post-infusion.","Pooled cohorts 6-9 (n=12) showed sustained BP reductions at 5 min, 30 min, and 24 hours (p≤0.0031).","No placental transfer; no serious TEAEs; mild nausea (14%), headache (11%), flushing (4%); no discontinuations.","Uterine artery pulsatility index reduced 13.2% (p=0.0003), indicating improved placental perfusion.","Study to proceed with dose expansion (Part 1b) and initiate fetal growth restriction cohort (Part 3)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153590,"accession_number":"0001437749-25-017239","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"DiaMedica shareholders elect all 7 director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael Giuffre, Rick Kuntz, Tanya Lewis, Daniel O'Connor, James Parsons, Rick Pauls, Charles Semba elected with 96.3% or more of votes cast.","Appointment of Baker Tilly US, LLP as auditor for FY2025 approved with 95.5% of votes cast.","Advisory vote on executive compensation passed with 94.1% of votes cast (excluding broker non-votes).","Quorum reached with 45.1% of outstanding shares (19.34M of 42.86M) present at May 15, 2025 AGM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153589,"accession_number":"0001437749-25-016487","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DiaMedica reports Q1 net loss $7.7M; preeclampsia Phase 2 topline data expected June-July 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.7M ($0.18/sh) vs $5.2M ($0.14) in Q1 2024; R&D expense rose to $5.7M on trial expansion.","Cash $37.3M as of Mar 31, 2025 (down from $44.1M Dec 2024); runway into Q3 2026.","Phase 2 preeclampsia Part 1A topline results expected between 2H June and 1H July 2025; KOL event May 28.","ReMEDy2 stroke trial enrollment progressing; interim analysis on first 200 patients expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172300,"accession_number":"0001437749-25-008014","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DiaMedica FY2024 net loss $24.4M; cash $44.1M; preeclampsia data Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.4M ($0.60/sh) vs $19.4M; R&D $19.1M, G&A $7.6M; no revenue.","Cash $44.1M at Dec 31, 2024; runway into Q3 2026; operating cash burn $22.1M.","Preeclampsia Phase 2 topline safety/efficacy data expected Q2 2025; dosing ongoing.","ReMEDy2 AIS trial: DSMB cleared new IV dosing; interim analysis of first 200 patients expected H1 2026.","Appointed Daniel J. O'Connor (former Ambrx CEO) to board in February 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172299,"accession_number":"0001437749-25-006379","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Richard Pilnik to retire from DiaMedica board at 2025 AGM","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Pilnik, director for over 15 years, will retire and not stand for re-election at the 2025 AGM, effective May 15, 2025.","His decision is not due to any disagreement with the company on operations, policies, or practices.","Chairman role already transitioned to James Parsons; board also recently added Daniel O'Connor as new director.","Board to re-evaluate committee composition and chair roles after Pilnik's departure for seamless transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172298,"accession_number":"0001437749-25-004891","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"DiaMedica Therapeutics appoints Daniel J. O'Connor to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel J. O'Connor appointed to Board effective Feb 20, 2025; joins Audit and Nominating & Corporate Governance Committees.","O'Connor previously served as CEO of Ambrx Biopharma, guiding it from $40M valuation to $2B acquisition by Johnson & Johnson in 14 months.","He received option to purchase 64,242 common shares at fair market value, vesting quarterly over three years.","Initial equity award for non-employee directors increased from 0.12% to 0.15% of outstanding common shares.","Non-employee director annual equity award also increased from 0.06% to 0.075% of outstanding common shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189295,"accession_number":"0001437749-24-034922","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"DiaMedica updates AIS trial protocol, delays interim readout to Q4 2025; Q3 R&D spend rises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expanded ReMEDy2 trial to include thrombolytic non-responders; interim analysis sample size increased to 200 from 144.","Top-line interim results now expected Q4 2025 (prior Summer 2025); interim analysis delayed.","Q3 2024 R&D expenses $5.0M (up from $3.3M YoY); G&A flat at $1.9M.","Cash, equivalents and investments $50.2M as of Sep 30, 2024; cash runway into Q3 2026.","Preeclampsia Phase 2 IST received SAHPRA approval; first patient dosed; top-line Part 1A results expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205789,"accession_number":"0001437749-24-025200","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DiaMedica updates on ReMEDy2 trial, starts preeclampsia study, extends cash to Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ReMEDy2 AIS interim analysis enrollment (n=144) targeted for Q1 2025; 15 top U.S. centers prioritized.","Phase 2 preeclampsia trial begins Q4 2024; proof-of-concept results expected H1 2025.","Completed $11.8M private placement ($2.50/share, ~10% premium) in June 2024; net proceeds $11.7M.","Cash, cash equivalents and investments $54.1M as of June 30, 2024; working capital $51.9M.","R&D expenses $3.9M for Q2 2024 (up from $2.5M Q2 2023); net cash used in operations $11.2M H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222758,"accession_number":"0001437749-24-021220","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"DiaMedica raises $11.8M in private placement at $2.50/share; funds stroke and preeclampsia trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $11.8M from sale of 4.72M shares at $2.50/share; expected close June 28, 2024.","Net proceeds to fund DM199 phase 2/3 ReMEDy2 trial for acute ischemic stroke and expansion into preeclampsia.","Cash runway extended into Q3 2026.","Non-management related parties committed $6.0M (2.4M shares); exempt from MI 61-101 valuation and minority approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222757,"accession_number":"0001437749-24-021219","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"DiaMedica Expands DM199 into Preeclampsia with Phase 2 Trial Starting Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 open-label, single-arm, investigator-sponsored trial enrolling up to 120 preeclampsia/FGR patients; first subject Q4 2024, topline results H1 2025.","Trial cost estimated at ~$1.5M; led by Prof. Catherine Cluver (Stellenbosch Univ.) with collaboration from Prof. Stephen Tong (Univ. Melbourne).","DM199 did not cross the placental barrier in rat studies; prior REDUX CKD data showed SBP reduction of 12.6 mmHg (p=0.004) in patients with baseline SBP ≥140 mmHg.","No approved therapeutics for preeclampsia in US/Europe; DM199 is a large-molecule protein (rhKLK1) that may improve placental perfusion and reduce hypoxia.","Company to host KOL event on July 29, 2024; conference call on June 27, 2024 at 8:00 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222756,"accession_number":"0001437749-24-018140","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"DiaMedica shareholders approve 3M share increase to 2019 Omnibus Incentive Plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to increase shares available under 2019 Omnibus Incentive Plan by 3,000,000 shares.","All seven director nominees elected with >13.5M votes each; broker non-votes of ~11.77M.","Baker Tilly US, LLP appointed as independent auditor for FY2024 with 24.97M votes for.","Advisory vote on executive compensation passed (13.18M for); shareholders prefer one-year say-on-pay frequency.","67.9% of outstanding shares (25.77M of 37.96M) voted at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222755,"accession_number":"0001437749-24-015378","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DiaMedica dosed first patient in ReMEDy2 stroke trial; Q1 cash $46.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First participant enrolled in relaunched ReMEDy2 Phase 2/3 trial of DM199 for acute ischemic stroke.","Cash, equivalents and investments of $46.5M as of March 31, 2024; working capital $44.9M.","Net cash used in operations was $6.7M in Q1 2024 vs $5.1M in Q1 2023, driven by vendor deposits for ReMEDy2.","R&D expenses $3.7M (up from $3.6M) and G&A $2.1M (up from $1.9M) compared to year-ago quarter.","Expect full enrollment for 144-patient interim analysis by Q1 2025; Canadian and Australian site activations on track for H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222754,"accession_number":"0001437749-24-011645","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DiaMedica Therapeutics SVP Julie VanOrsdel Daves resigns; Rebekah de Vitry Fries assumes clinical operations leadership","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Julie VanOrsdel Daves resigns as SVP, Clinical Development Operations effective April 18, 2024 for personal reasons.","Rebekah de Vitry Fries, current VP of Clinical Operations, will assume leadership of clinical operations.","De Vitry Fries joined DiaMedica as a consultant on Jan 3, 2024 and became full-time employee on Feb 20, 2024.","She previously served as Head of Clinical Operations at Epygenix Therapeutics, reporting to same CMO Lorianne Musuoka."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242238,"accession_number":"0001437749-24-008521","cik":1401040,"company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"DiaMedica FY2023: $52.9M cash, ReMEDy2 interim enrollment Q1 2025, CMO hired","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $52.9M at Dec 31, 2023, up from $33.5M; net cash used in ops $18.7M.","R&D expenses $13.1M (up 68% YoY) due to in-use studies and DM199 manufacturing; G&A $8.2M (up 32%).","ReMEDy2 Phase 2/3 trial: 6 U.S. sites open; interim enrollment of 144 patients expected by Q1 2025.","Protocol modified to focus on moderate AIS (NIHSS 5-15) and exclude posterior strokes to boost efficacy.","Appointed Dr. Lorianne Masuoka as CMO in Jan 2024 and Rebekah de Vitry Fries as VP Clinical Operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":329766052.83934426,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}